Sativex fails Phase III trial to treat Cancer Pain- GW Pharma
GW Pharmaceuticals PLC announced that one of three Phase III cancer pain trials of its Sativex (delta-9-tetrahydrocannabinol and cannabidiol) failed to meet its primary endpoint, although two more trials are ongoing, and are on track for its Epidiolex programme. The company, along with Otsuka Pharmaceutical Development & Commercialization Inc., said that one of its phase III trials of Sativex as an adjunctive treatment to optimised chronic opioid therapy failed to show a statistically significant difference from a placebo. Despite this, GW Pharmaceuticals expressed confidence in Sativex underpinned by positive data from its Phase II programme. Two further trials are ongoing, and the company said that if those are positive, this would still allow it to submit a new drug application with the FDA.
Related news and insights
AcuPebble SA100, a small wearable device that enables automated, remote home testing to detect obstructive sleep apnoea (OSA) in adults, has obtained FDA clearance as a Class II medical device in the USA.
New data from the phase III GEM-3 trial of Vyjuvek (beremagene geperpavec), from Krystal Biotech, for the treatment of patients with dystrophic epidermolysis bullosa has met its primary endpoint of complete wound healing at the six-month mark.
Bristol Myers Squibb announced that the FDA has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for BMS 986165 (deucravacitinib) for the treatment of adults with moderate to severe plaque psoriasis.